Kane’s DispersinB passes biocompatibility tests

Kane Biotech’s (TSX-V:KNE) DispersinB’s topical wound spray has passed FDA-recommended cytotoxicity, primary skin irritation and genotoxicity tests, with two remaining biocompatibility studies currently in progress. “Biocompatibility is critical to the commercial development of a topical wound care product and these results confirm that DispersinB spray is non-cytotoxic, non-irritant, non-mutagenic and non-genotoxic,” CSO Dr. Sri Madhyastha [...]

In conversation with Gord Froehlich

After a 25-year stint with Monsanto Canada, where he rose to vice president, Gord Froehlich moved seamlessly into Kane Biotech (TSX-V: KNE) as VP of Business Development and then into the executive suite in 2006. While there is a myriad of differences between a biotech start-up and a global ag-biotech giant, Mr. Froehlich contends that [...]